From: Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2
 | COVID- HIV- | COVID- HIV+ | COVID+ HIV- | Overall |
---|---|---|---|---|
 | n = 46 | n = 10 | n = 56 | n = 112 |
Sex | ||||
 Female | 28 (60.9%) | 1 (10%) | 31 (55.4%) | 60 |
 Male | 18 (39.1%) | 9 (90%) | 25 (44.6%) | 52 |
Age | ||||
 Mean (SD) | 46.7 (13.4) | 58.6 (5.3) | 58.7 (20.4) | 53.8 (17.8) |
 Median [Min, Max] | 48.0 [19.0, 68.0] | 58.0 [48.0,65.0] | 57.5 [24.0, 98.0] | 54.5 [19.0,98.0] |
Race | ||||
 Asian | 8 (17.4%) | 0 (0%) | 3 (5.4%) | 11 (9.8%) |
 Black | 10 (21.7%) | 4 (40%) | 16 (28.6%) | 30 (26.8%) |
 LatinX | 0 (0%) | 0 (0%) | 5 (8.9%) | 5 (4.5%) |
 Unknown/Other | 8 (17.4%) | 1 (10%) | 8 (14.3%) | 17 (15.2%) |
 White | 20 (43.5%) | 5 (50%) | 24 (42.9%) | 49 (43.8%) |